This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Health Winners & Losers: ImClone

Buyout fever launched biotech stocks higher Thursday, pushing earnings to the back burner for a day.

The Amex biotechnology index rallied 4.1% to 864.14. The rally got started early when Bristol-Myers Squibb (BMY) announced a $60-a-share bid to buy ImClone (IMCL), valuing the biotech company at $5.2 billion.

Shares of ImClone, a component of the Nasdaq biotech index, soared $17.49, or 37.7%, to $63.93 while Bristol shares gave up 39 cents, or 1.8%, to $63.93.

The buyout enthusiasm spilled over to other stocks as investors pondered the possibility other such Big Pharma-biotech mergers. Amylin (AMLN) and Onyx (ONXX) gained 14.8% and 10%, respectively.

In clinical and regulatory news, Genmab and GlaxoSmithKline (GSK - Get Report) reported positive preliminary results from a late-stage trial on ofatumumab for patients with chronic lymphocytic leukaemia, or CLL, and said they plan to file for U.S. and European regulatory approval by the end of the year.

If approved, the drug could compete with Genentech (DNA) and Biogen Idec's (BIIB) Rituxan.

Glaxo shares ended essentially flat, while Biogen Idec fell $1.51, or 2%, to $69.76 and Genentech edged up 25 cents, or 0.3%, to $95.25.

A legal and regulatory item, generic-drug maker Barr Pharmaceuticals (BRL) is striking again. The company said it is challenging a patent held by Belgian drug maker UCB Inc. for 5-mg tablets of hay fever treatment Xyzal. UCB filed a patent infringement lawsuit against Barr on Wednesday. The drug was developed by Sepracor (SEPR) and licensed to UCB. Sanofi-Aventis (SNY) markets it in the U.S.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
CADX $0.00 0.00%
ONXX $0.00 0.00%
IMCL $3.80 26.67%
AZN $70.76 -1.43%
GSK $46.85 0.56%

Markets

DOW 18,037.97 -42.17 -0.23%
S&P 500 2,108.92 -8.77 -0.41%
NASDAQ 5,060.2460 -31.8390 -0.63%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs